Prothena (PRTA) Stock Forecast & Price Target $16.80 +0.12 (+0.72%) (As of 10/3/2024 ET) Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Prothena - Analysts' Recommendations and Stock Price Forecast (2024) How MarketBeat Calculates Price Target and Consensus Rating MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 7 Analyst RatingsSell0Hold2Buy5 Based on 7 Wall Street analysts who have issued ratings for Prothena in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 2 have given a hold rating, and 5 have given a buy rating for PRTA. Consensus Price Target $61.86268.20% Upside According to the 7 analysts' twelve-month price targets for Prothena, the average price target is $61.86. The highest price target for PRTA is $87.00, while the lowest price target for PRTA is $24.00. The average price target represents a forecasted upside of 268.20% from the current price of $16.80. Get the Latest News and Ratings for PRTA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Prothena and its competitors. Enter your email to sign up for newsletter Sign Up PRTA Analyst Ratings Over TimeTypeCurrent Forecast10/5/23 to 10/4/241 Month Ago9/5/23 to 9/4/243 Months Ago7/7/23 to 7/6/241 Year Ago10/5/22 to 10/5/23Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy5 Buy rating(s)5 Buy rating(s)5 Buy rating(s)7 Buy rating(s)Hold2 Hold rating(s)2 Hold rating(s)2 Hold rating(s)1 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$61.86$62.86$66.00$90.38Forecasted Upside268.20% Upside200.75% Upside225.77% Upside92.12% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy Trade Alongside Pelosi, Buffett, and More (Ad)People don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, Bill Ackman, Steve Cohen and more. They also don’t know that they can learn how it’s done and receive daily, AI powered trade alerts for free! All because of one trading veteran that set up a free newsletter designed to level the playing field.Sign up takes less than 10 seconds, and you’ll start getting his alerts and market insights absolute PRTA Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History PRTA Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Prothena Stock vs. The CompetitionTypeProthenaMedical CompaniesS&P 500Consensus Rating Score 2.71 2.78 2.50Consensus RatingModerate BuyModerate BuyHoldPredicted Upside268.20% Upside850.33% Upside7.73% UpsideNews Sentiment RatingNeutral NewsSee Recent PRTA NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails10/1/2024HC Wainwright2 of 5 stars Reiterated RatingBuy ➝ Buy$84.00 ➝ $84.00+402.09%10/1/2024Bank of America4 of 5 stars Lower TargetNeutral ➝ Neutral$33.00 ➝ $31.00+85.30%9/30/2024Cantor Fitzgerald3 of 5 stars Reiterated RatingOverweight8/14/2024OppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOutperform ➝ Outperform$66.00 ➝ $62.00+210.31%8/9/2024Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetSector Perform ➝ Sector Perform$28.00 ➝ $24.00+18.34%5/9/2024JMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetMarket Outperform ➝ Market Outperform$85.00 ➝ $83.00+280.21% Get the Latest News and Ratings for PRTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. 12/12/2023Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$62.00+76.24%4/24/2023Leerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingR. LiSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/24/2023SVB SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageOutperform$80.00+46.74%2/27/2023CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy$76.00 ➝ $72.00+31.94%1/27/2023Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageOverweight$94.00+68.31%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:23 AM ET. PRTA Forecast - Frequently Asked Questions What is Prothena's forecast for 2024? According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Prothena is $61.86, with a high forecast of $87.00 and a low forecast of $24.00. Should I buy or sell Prothena stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares. Does Prothena's stock price have much upside? According to analysts, Prothena's stock has a predicted upside of 268.20% based on their 12-month stock forecasts. What analysts cover Prothena? Prothena has been rated by research analysts at Bank of America, Cantor Fitzgerald, HC Wainwright, Oppenheimer, and Royal Bank of Canada in the past 90 days. Do Wall Street analysts like Prothena more than its competitors? Analysts like Prothena less than other "medical" companies. The consensus rating score for Prothena is 2.71 while the average consensus rating score for "medical" companies is 2.78. Learn more on how PRTA compares to other companies. Stock Forecasts and Research Tools Related Companies: Dynavax Technologies Stock Forecast UroGen Pharma Stock Forecast Akebia Therapeutics Stock Forecast Puma Biotechnology Stock Forecast Marinus Pharmaceuticals Stock Forecast Immunovant Stock Forecast Avidity Biosciences Stock Forecast Crinetics Pharmaceuticals Stock Forecast Cybin Stock Forecast TG Therapeutics Stock Forecast Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter 44-year Wall Street Vet: “Permanent devastation is coming to America” (Ad)After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.The information in this video is crucially valuable. This page (NASDAQ:PRTA) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, B...Bullseye Trades | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMassive NVIDIA Sell-Off: Are We Headed for a Market Collapse?You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this ye...Behind the Markets | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.